EVO ICL Sponsors Jonas Brothers’ The Tour
04 Maio 2023 - 8:00AM
Business Wire
EVO ICL, the vision correction procedure that works in harmony
with your natural eye, provides sharp, clear vision day or night
and does not cause contact lens induced dry eye or dry eye
syndrome, announced today sponsorship of the Jonas Brothers’ The
Tour in North America, which begins August 12. Collaboration with
the group will also include a new EVO advertising campaign slated
for launch in the fall of 2023. The campaign will help drive
education and awareness of EVO among the millions of Americans who
suffer from myopia and are looking for a proven and effective
vision correction solution.
Tom Frinzi, CEO of STAAR Surgical shared, "In 2022, Joe Jonas
chose EVO ICL for his vision correction procedure and the day after
texted his brother Kevin that he needed to get EVO ICLs too. The
fact that they both chose EVO ICLs for their vision correction
makes us proud in knowing that their ability to connect with their
fans on The Tour is even further enhanced due to the sharp, clear
vision EVO lenses deliver. In addition, we are quite pleased to
create a new EVO advertising campaign with all three brothers that
we will launch around the time of The Tour."
“Doing EVO ICL was the best decision – it is amazing being able
to see so clearly especially when we’re performing on stage. We’re
excited to have EVO onboard for The Tour,” said Joe and Kevin.
While the EVO ICL lens is new to the US market, it has been
approved, marketed and successfully implanted by ophthalmologists
throughout Europe, Asia, and the rest of the world. According to a
patient survey, 99.4% of patients would have the EVO ICL procedure
again.* Over 2,000,000 ICLs have been sold globally.
For more information about EVO® Implantable Collamer® Lenses,
visit https://DiscoverEVO.com.
* Packer M. The Implantable Collamer Lens with a central port:
review of the literature. Clinical Ophthalmology 2018: 12:
2427–2438.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™
product line. More than 2,000,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: www.discovericl.com. Headquartered in Lake
Forest, CA, the company operates manufacturing and packaging
facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.
For more information, please visit the Company’s website at
www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: product safety, effectiveness, or performance for any
particular patient, and any statements of assumptions underlying
any of the foregoing. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include risks factors set forth in the
Company’s Annual Report on Form 10-K for the year ended December
30, 2022 under the caption “Risk Factors,” which is on file with
the Securities and Exchange Commission and available in the
“Investor Information” section of the company’s website under the
heading “SEC Filings.” We disclaim any intention or obligation to
update or revise any forward-looking statements due to new
information or events. These statements are based on expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those described in the
forward-looking statements.
Important Safety Information for EVO
ICL
The EVO ICL lens is intended to correct/reduce nearsightedness
between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to
4.0 D. If you have nearsightedness within these ranges, EVO ICL
surgery may improve your distance vision without eyeglasses or
contact lenses. Because the EVO ICL corrects for distance vision,
it does not eliminate the need for reading glasses, you may require
them at some point, even if you have never worn them before. Since
implantation of the EVO ICL is a surgical procedure, before
considering EVO ICL surgery you should have a complete eye
examination and talk with your eye care professional about EVO ICL
surgery, especially the potential benefits, risks, and
complications. You should discuss the time needed for healing after
surgery. Complications, although rare, may include need for
additional surgical procedures, inflammation, loss of cells from
the back surface of the cornea, increase in eye pressure, and
cataracts. You should NOT have EVO ICL surgery if your doctor
determines that 1) the shape of your eye is not appropriate, 2) you
do not meet the minimum endothelial cell density for your age at
the time of implantation, 3) you have moderate to severe glaucoma,
4) your vision is not stable; or 5) if you are pregnant or
nursing.
For additional information with potential benefits, risks and
complications please visit DiscoverICL.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504005491/en/
Media and Investors Brian Moore Vice President, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024